Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled riliprubart trial in refractory CIDP
2023-506503-26-00Phase 3Authorised
- Sponsor
- Sanofi
- Start
- Jul 2024
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial in chronic inflammatory demyelinating polyneuropathy (CIDP) comparing Riliprubart with Placebo (2 arms). Primary endpoints: Percentage of participants experiencing a response, Percentage of participants randomized to riliprubart with lasting response and 1 more. Planned start Jul 2024; status: authorised.
02
Drugs
riliprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2023-506503-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506503-26-00.